Your healthcare provider may do a chest x-ray if you have any of these symptoms. Tell your healthcare provider if you have any new or worsening symptoms of lung problems, including shortness of breath, fever, cough, or wheezing. Your healthcare provider may stop treatment with LYNPARZA until your blood cell counts improve weekly if you have low blood cell counts that last a long time.every month during treatment with LYNPARZA.Your healthcare provider will do blood tests to check your blood cell counts: Symptoms may include weakness, weight loss, fever, frequent infections, blood in urine or stool, shortness of breath, feeling very tired, bruising or bleeding more easily. Symptoms of low blood cell counts are common during treatment with LYNPARZA, but can be a sign of serious bone marrow problems, including MDS or AML. It is not known if LYNPARZA is safe and effective in children. Your healthcare provider will perform a test to make sure that LYNPARZA is right for you LYNPARZA is used in combination with another anti-cancer medicine, abiraterone, together with the steroid medicine, prednisone or prednisolone. prostate cancer with a certain type of abnormal inherited or acquired BRCA gene that has spread to other parts of the body (metastatic) and no longer responds to a medical or surgical treatment that lowers testosterone.LYNPARZA is used when the cancer has spread to other parts of the body (metastatic), and no longer responds to a medical or surgical treatment that lowers testosterone, and has progressed after treatment with enzalutamide or abiraterone. prostate cancer with certain inherited or acquired abnormal genes called homologous recombination repair (HRR genes).LYNPARZA is used as a maintenance treatment after your cancer has not progressed on at least 16 weeks of treatment with platinum-based chemotherapy. metastatic pancreatic cancer with a certain type of abnormal inherited BRCA gene.If you have hormone receptor (HR)-positive disease, you should have been treated with hormonal therapy. You should have received chemotherapy medicines, either before or after your cancer has spread. a certain type of abnormal inherited BRCA gene, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has spread to other parts of the body (metastatic).You should have received chemotherapy medicines before or after surgery to remove the tumor. LYNPARZA is given after surgery (treatment after surgery is called adjuvant therapy). human epidermal growth factor receptor 2 (HER2)-negative early breast cancer with a certain type of inherited (germline) abnormal BRCA gene.

LYNPARZA is used after the cancer has responded to treatment with platinum-based chemotherapy. LYNPARZA is used as maintenance treatment when the cancer has come back. ovarian cancer, fallopian tube cancer, or primary peritoneal cancer with a certain type of inherited (germline) or acquired (somatic) abnormal BRCA gene.LYNPARZA is used in combination with another anti-cancer medicine, bevacizumab, as maintenance treatment after the cancer has responded to your first treatment with platinum-based chemotherapy. advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer with a certain type of abnormal BRCA gene or a positive laboratory tumor test for genomic instability called HRD.LYNPARZA is used alone as maintenance treatment after the cancer has responded to your first treatment with platinum-based chemotherapy. advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer with a certain type of inherited (germline) or acquired (somatic) abnormal BRCA gene.LYNPARZA is a prescription medicine used to treat adults who have:

Grapefruit and cholesterol meds